


CLAIMS

1. A compound having structural formula I:



or a pharmaceutically acceptable salt thereof, wherein:

each of R^1 , R^2 and R^3 is independently selected from $-CH_3$, and $-CD_3$; and

each of Y^{1a} , Y^{1b} , Y^{2a} , Y^{2b} , Y^{3a} , Y^{3b} , Y^{4a} , Y^{4b} , Y^{4c} , and Y^{4d} is independently selected from hydrogen and deuterium;

wherein each position that is designated as containing deuterium has at least 50.1% deuterium incorporation at that position and at least R^1 or both R^2 and R^3 are CD_3 .

2. The compound of claim 1, wherein:

Y^{1a} and Y^{1b} are the same;

Y^{2a} and Y^{2b} are the same;


Y^{3a} and Y^{3b} are the same; and

Y^{4a} , Y^{4b} , Y^{4c} , and Y^{4d} are the same.


3. The compound of claim 1, wherein each of Y^{4a} , Y^{4b} , Y^{4c} , and Y^{4d} is hydrogen.

4. The compound of claim 1, wherein each of Y^{1a} and Y^{1b} is deuterium, each of Y^{1a} and Y^{1b} is hydrogen, each of Y^{2a} and Y^{2b} is deuterium, each of Y^{2a} and Y^{2b} is hydrogen, each of Y^{3a} and Y^{3b} is deuterium, or each of Y^{3a} and Y^{3b} is hydrogen.

5. The compound of claim 1, wherein R^1 is $-CD_3$.
6. The compound of claim 1, wherein each of R^2 and R^3 is $-CD_3$, or each of R^2 and R^3 is $-CH_3$.
7. The compound of claim 1, wherein each of Y^{4a} , Y^{4b} , Y^{4c} , and Y^{4d} is deuterium, Y^{1a} and Y^{1b} are the same; Y^{2a} and Y^{2b} are the same; Y^{3a} and Y^{3b} are the same; and R^2 and R^3 are the same.
8. The compound of claim 7, wherein the compound is selected from:



and



or a pharmaceutically

acceptable salt thereof.


9. The compound of claim 1, wherein each of Y^{4a} , Y^{4b} , Y^{4c} , and Y^{4d} is hydrogen; Y^{1a} and Y^{1b} are the same; Y^{2a} and Y^{2b} are the same; Y^{3a} and Y^{3b} are the same; and R^2 and R^3 are the same, the compound selected from any compound in the table below:

Compound	Y^{1a}/Y^{1b}	Y^{2a}/Y^{2b}	Y^{3a}/Y^{3b}	R^1	R^2/R^3
103	H	H	H	CD_3	CH_3
104	H	H	H	CH_3	CD_3
107	D	H	H	CD_3	CH_3
108	D	H	H	CH_3	CD_3
110	H	D	H	CD_3	CH_3
111	H	D	H	CH_3	CD_3
112	H	H	D	CD_3	CH_3
113	H	H	D	CH_3	CD_3
114	H	H	H	CD_3	CD_3
116	D	D	H	CD_3	CH_3
117	D	D	H	CH_3	CD_3
118	D	H	D	CD_3	CH_3
119	D	H	D	CH_3	CD_3
120	D	H	H	CD_3	CD_3
121	H	D	D	CD_3	CH_3


Compound	Y ^{1a} /Y ^{1b}	Y ^{2a} /Y ^{2b}	Y ^{3a} /Y ^{3b}	R ¹	R ² /R ³
122	H	D	D	CH ₃	CD ₃
123	H	D	H	CD ₃	CD ₃
124	H	H	D	CD ₃	CD ₃
125	D	D	D	CD ₃	CH ₃
126	D	D	D	CH ₃	CD ₃
127	D	D	H	CD ₃	CD ₃
128	D	H	D	CD ₃	CD ₃
129	H	D	D	CD ₃	CD ₃
130	D	D	D	CD ₃	CD ₃

wherein any atom not designated as deuterium or D is present at its natural isotopic abundance.

10. The compound of claim 9, wherein the compound is selected from:



11. The compound of claim 1, having structural formula Ia:



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from $-CH_3$, and $-CD_3$;


Y^{1a} and Y^{1b} are the same; and

Y^{2a} and Y^{2b} are the same.

12. The compound of claim 11, wherein Y^{2a} and Y^{2b} are hydrogen.


13. The compound of claim 11, wherein R^1 is $-CD_3$ and each of Y^{1a} and Y^{1b} is deuterium, or R^1 is $-CH_3$ and each of Y^{1a} and Y^{1b} is hydrogen.

14. The compound of claim 11, having the following structural formula:



or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1, having structural formula Ib:



, or a pharmaceutically acceptable salt thereof, wherein:

each of R^2 and R^3 is independently selected from $-CH_3$ and $-CD_3$;


Y^{2a} and Y^{2b} are the same; and

Y^{3a} and Y^{3b} are the same.

16. The compound of claim 15, wherein Y^{2a} and Y^{2b} are hydrogen, or Y^{3a} and Y^{3b} are hydrogen.

17. The compound of claim 15, wherein R^2 and R^3 are the same.

18. The compound of claim 15 having the following structural formula



or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1, wherein any atom not designated as deuterium or D is present at its natural isotopic abundance.

20. The compound of claim 1, wherein each position designated as D has greater than 90% deuterium incorporation.

21. A pharmaceutical composition comprising a compound of claim 1; and a pharmaceutically acceptable carrier.

22. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cutaneous T-cell lymphoma.
23. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for enhancing an immune response to an antigen in a subject, wherein the medicament is to be conjointly administered with the antigen to the subject.
24. The use of claim 23, wherein the antigen is selected from a cancer antigen, an influenza antigen and a Hepatitis B virus antigen.
25. The use of claim 23, wherein the cancer antigen is selected from NY-ESO-1 protein, NY-ESO-1b peptide, gp100, MAGE-3, CDX-1401, LPV7, and an autologous tumor lysate.
26. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be conjointly administered with a second therapeutic agent selected from an immunotherapy agent and a therapeutic antibody.
27. The use of claim 26, wherein the immunotherapy agent is a checkpoint inhibitor.
28. The use of claim 26, wherein the therapeutic antibody is selected from an antibody selective for EGFR and an antibody selective for Her 2.
29. A compound of claim 1 or a pharmaceutically acceptable salt thereof, for use in therapy.